Athanassios Argiris

12.4k total citations · 1 hit paper
243 papers, 8.9k citations indexed

About

Athanassios Argiris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Athanassios Argiris has authored 243 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 154 papers in Oncology, 119 papers in Pulmonary and Respiratory Medicine and 105 papers in Otorhinolaryngology. Recurrent topics in Athanassios Argiris's work include Head and Neck Cancer Studies (105 papers), Lung Cancer Treatments and Mutations (90 papers) and Lung Cancer Research Studies (43 papers). Athanassios Argiris is often cited by papers focused on Head and Neck Cancer Studies (105 papers), Lung Cancer Treatments and Mutations (90 papers) and Lung Cancer Research Studies (43 papers). Athanassios Argiris collaborates with scholars based in United States, Greece and United Kingdom. Athanassios Argiris's co-authors include Robert L. Ferris, Michalis V. Karamouzis, David Raben, Jennifer R. Grandis, Arlene A. Forastiere, William E. Gooding, Everett E. Vokes, John R. Murren, Daniel J. Haraf and Barbara Burtness and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Athanassios Argiris

241 papers receiving 8.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Head and neck cancer

2008 1.8k citations Athanassios Argiris, Michalis V. Karamouzis et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Athanassios Argiris United States	47	4.2k	3.5k	2.8k	2.7k	2.2k	243	8.9k
Nabil F. Saba United States	46	4.1k 1.0×	3.1k 0.9×	2.5k 0.9×	2.5k 0.9×	2.6k 1.2×	406	9.2k
Makoto Tahara Japan	43	4.1k 1.0×	2.1k 0.6×	3.1k 1.1×	1.5k 0.6×	2.2k 1.0×	379	9.0k
Ricard Mesı́a Spain	31	4.0k 0.9×	4.1k 1.2×	3.0k 1.1×	1.6k 0.6×	2.4k 1.1×	164	7.8k
Sylvie Rottey Belgium	39	4.1k 1.0×	2.2k 0.6×	3.1k 1.1×	2.2k 0.8×	1.6k 0.8×	236	7.9k
Francis P. Worden United States	49	3.5k 0.8×	3.5k 1.0×	2.3k 0.8×	1.7k 0.6×	3.1k 1.4×	257	9.1k
Stephen Y. Lai United States	51	2.7k 0.6×	2.1k 0.6×	1.9k 0.7×	1.9k 0.7×	2.0k 0.9×	271	8.3k
Charles Lu United States	32	3.1k 0.7×	4.2k 1.2×	2.7k 1.0×	1.5k 0.6×	2.5k 1.2×	100	8.3k
Edwin P. Hui Hong Kong	47	4.0k 0.9×	3.2k 0.9×	1.8k 0.6×	2.2k 0.8×	2.1k 1.0×	170	8.9k
Julie E. Bauman United States	36	2.7k 0.6×	1.8k 0.5×	1.6k 0.6×	2.6k 1.0×	1.2k 0.6×	140	6.6k
Brigette Ma Hong Kong	53	4.9k 1.1×	3.1k 0.9×	2.3k 0.8×	2.7k 1.0×	2.3k 1.1×	243	10.2k

Countries citing papers authored by Athanassios Argiris

Since Specialization

Citations

This map shows the geographic impact of Athanassios Argiris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Athanassios Argiris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Athanassios Argiris more than expected).

Fields of papers citing papers by Athanassios Argiris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Athanassios Argiris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Athanassios Argiris. The network helps show where Athanassios Argiris may publish in the future.

Co-authorship network of co-authors of Athanassios Argiris

This figure shows the co-authorship network connecting the top 25 collaborators of Athanassios Argiris. A scholar is included among the top collaborators of Athanassios Argiris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Athanassios Argiris. Athanassios Argiris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manukian, Gregor, Jennifer M. Johnson, Rita Axelrod, et al.. (2023). In-Field Toxicity Analysis of a Phase 1 Clinical Trial of Nivolumab and Ipilimumab With Definitive Radiation Therapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 117(1). 181–185. 3 indexed citations

Vathiotis, Ioannis, Jennifer M. Johnson, Adam Luginbuhl, et al.. (2022). Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches. Cancer Treatment Reviews. 109. 102437–102437. 2 indexed citations

Argiris, Athanassios, Ju‐Whei Lee, James Stevenson, et al.. (2017). Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508). Annals of Oncology. 28(12). 3037–3043. 14 indexed citations

Wong, Stuart J., Theodore Karrison, D. Neil Hayes, et al.. (2015). Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Annals of Oncology. 27(2). 318–323. 73 indexed citations

Schuler, Patrick J., Malgorzata Harasymczuk, Carmen Visús, et al.. (2014). Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer. Clinical Cancer Research. 20(9). 2433–2444. 120 indexed citations

Egloff, Ann Marie, Ju-Whei Lee, Corey J. Langer, et al.. (2014). Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research. 20(19). 5041–5051. 26 indexed citations

Gross, Neil D., Julie E. Bauman, William E. Gooding, et al.. (2014). Erlotinib, Erlotinib–Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. Clinical Cancer Research. 20(12). 3289–3298. 39 indexed citations

Wheeler, Sarah, Doris R. Siwak, Raymond L. Chai, et al.. (2012). Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 18(8). 2278–2289. 63 indexed citations

Bhola, Neil E., Sufi M. Thomas, Maria L. Freilino, et al.. (2011). Targeting GPCR-Mediated p70S6K Activity May Improve Head and Neck Cancer Response to Cetuximab. Clinical Cancer Research. 17(15). 4996–5004. 25 indexed citations

10.

Vaezi, Alec, Shama Buch, William E. Gooding, et al.. (2011). XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 17(16). 5513–5522. 42 indexed citations

11.

Argiris, Athanassios, Michalis V. Karamouzis, William E. Gooding, et al.. (2011). Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. Journal of Clinical Oncology. 29(9). 1140–1145. 84 indexed citations

12.

Argiris, Athanassios, Austin G. Duffy, Shivaani Kummar, et al.. (2011). Early Tumor Progression Associated with Enhanced EGFR Signaling with Bortezomib, Cetuximab, and Radiotherapy for Head and Neck Cancer. Clinical Cancer Research. 17(17). 5755–5764. 44 indexed citations

13.

Lara, Primo N., Jeff Longmate, Karen L. Reckamp, et al.. (2011). Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial. Clinical Lung Cancer. 12(1). 33–37. 17 indexed citations

14.

Chung, Christine H., Erin H. Seeley, Heinrich Röder, et al.. (2010). Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients. Cancer Epidemiology Biomarkers & Prevention. 19(2). 358–365. 51 indexed citations

15.

Tarhini, Ahmad A. & Athanassios Argiris. (2010). Maintenance Therapy for Advanced-Non Small Cell Lung Cancer. 3(1). 4 indexed citations

16.

Mountzios, Giannis, Taofeek K. Owonikoko, Michalis V. Karamouzis, & Athanassios Argiris. (2010). Current and Emerging Roles of Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small Cell Lung Cancer. 3(1). 1 indexed citations

17.

Lai, Stephen Y., Priya Koppikar, Sufi M. Thomas, et al.. (2009). Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. Journal of Clinical Oncology. 27(8). 1235–1242. 46 indexed citations

18.

Argiris, Athanassios, Michalis V. Karamouzis, David Raben, & Robert L. Ferris. (2008). Head and neck cancer. The Lancet. 371(9625). 1695–1709. 1827 indexed citations breakdown →

19.

Argiris, Athanassios, et al.. (2004). Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung Cancer. 43(3). 317–322. 44 indexed citations

20.

Argiris, Athanassios, Peter Heald, Timothy M. Kuzel, et al.. (2001). Phase II Trial of 9-Aminocamptothecin as a 72-h Infusion in Cutaneous T-Cell Lymphoma. Investigational New Drugs. 19(4). 321–326. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact